EDAP Will Go To FDA Panel In July For HIFU Prostate Cancer Device
This article was originally published in The Gray Sheet
Executive Summary
Data for the French firm’s Ablatherm-HIFU for treating localized prostate cancer will be discussed by the agency’s Gastroenterology and Urology Device Panel this summer.